First Time Loading...

AstraZeneca PLC
LSE:AZN

Watchlist Manager
AstraZeneca PLC Logo
AstraZeneca PLC
LSE:AZN
Watchlist
Price: 10 710 GBX -0.3%
Updated: Mar 28, 2024

Relative Value

The Relative Value of one AZN stock under the Base Case scenario is 18 144.64 GBX. Compared to the current market price of 10 710 GBX, AstraZeneca PLC is Undervalued by 41%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

AZN Relative Value
Base Case
18 144.64 GBX
Undervaluation 41%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
49
vs Industry
27
Median 3Y
4.7
Median 5Y
4.7
Industry
2.4
Forward
0
vs History
66
vs Industry
12
Median 3Y
38.2
Median 5Y
45.7
Industry
22.3
Forward
0.2
vs History
77
vs Industry
22
Median 3Y
22.4
Median 5Y
26.1
Industry
16.8
vs History
71
vs Industry
12
Median 3Y
40.2
Median 5Y
43
Industry
20.5
vs History
71
vs Industry
13
Median 3Y
5.5
Median 5Y
6.5
Industry
2
vs History
84
vs Industry
6
Median 3Y
46.9
Median 5Y
49.2
Industry
2.6
Forward
0.4
vs History
88
vs Industry
4
Median 3Y
59.2
Median 5Y
61.1
Industry
5.1
vs History
88
vs Industry
1
Median 3Y
153.9
Median 5Y
158.3
Industry
13.2
Forward
1.1
vs History
88
vs Industry
0
Median 3Y
274.6
Median 5Y
287.3
Industry
16.1
Forward
1.3
vs History
84
vs Industry
1
Median 3Y
238.6
Median 5Y
325.1
Industry
15
vs History
79
vs Industry
2
Median 3Y
345.7
Median 5Y
527.3
Industry
15.8
vs History
79
vs Industry
5
Median 3Y
29.6
Median 5Y
29.8
Industry
2

Multiples Across Competitors

AZN Competitors Multiples
AstraZeneca PLC Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
UK
AstraZeneca PLC
LSE:AZN
166B GBP 4.6 35.2 138.9 222.8
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY 4 211 733 -5 347 888.9 -5 459 134.4 -5 046 864.6
US
Eli Lilly and Co
NYSE:LLY
738.8B USD 21.7 141 63.6 73
DK
Novo Nordisk A/S
CSE:NOVO B
3.9T DKK 16.9 47 34.3 37.4
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
380.2B USD 4.5 10.8 12.1 15.9
US
Merck & Co Inc
NYSE:MRK
333.5B USD 5.5 913.8 45.4 88.6
CH
Roche Holding AG
SIX:ROG
181.8B CHF 3.1 15.8 8.7 10.3
CH
Novartis AG
SIX:NOVN
178.2B CHF 4.2 13.2 9.7 16
US
Pfizer Inc
NYSE:PFE
156.8B USD 2.7 74 11.1 16.6
FR
Sanofi SA
PAR:SAN
114.4B EUR 2.5 21.3 8 11.7
P/E Multiple
Earnings Growth
UK
AstraZeneca PLC
LSE:AZN
Average P/E: 141.3
35.2
172%
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 347 888.9 N/A
US
Eli Lilly and Co
NYSE:LLY
141
340%
DK
Novo Nordisk A/S
CSE:NOVO B
47
77%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A
US
Johnson & Johnson
NYSE:JNJ
10.8
-21%
US
Merck & Co Inc
NYSE:MRK
913.8
7 433%
CH
Roche Holding AG
SIX:ROG
15.8
27%
CH
Novartis AG
SIX:NOVN
13.2
18%
US
Pfizer Inc
NYSE:PFE
74
679%
FR
Sanofi SA
PAR:SAN
21.3
121%

See Also

Discover More